About Orphazyme

Company Description

Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.

We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC).

In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.

Year founded



Ole Maaløes Vej 3, 2200 Copenhagen – Denmark

Shareholder information

Shares outstanding



Jan. 1, 2000

Stock exchange(s)

Nasdaq Copenhagen



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.